RxDoctor Payments Data

Eveline Stock, MD

Cardiovascular Disease · San Francisco, CANPI 1487686911

Payments from drug & device makers

$281,837in general payments, 2019–2025

Across 26 payments — averaging $10,840 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$271K
  • Amgen$11K
  • Boehringer Ingelheim$30

What the payments were for

  • Consulting fees$1,34489%
  • Food & beverage$1178%
  • Education$423%

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis24$270,503
Amgen1$11,305
Boehringer Ingelheim1$30

How this compares

$281,837 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$86,504
Medicare patients
676
Services billed
1,229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab162$174,885
Praluent PenAlirocumab85$81,417
JardianceEmpagliflozin21$34,460
WegovySemaglutide18$28,793
EliquisApixaban23$28,507
NexletolBempedoic Acid24$18,187
VascepaIcosapent Ethyl15$10,484
XareltoRivaroxaban14$7,742
Icosapent Ethyl17$6,490
Ezetimibe161$5,961
Rosuvastatin Calcium157$2,215
Metoprolol Succinate67$1,233
Atorvastatin Calcium89$1,096
Omega-3 Acid Ethyl Esters12$982
Irbesartan17$501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$30$34,46021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →